Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: a significant tariff impact on financial projections, a reduction in EBITDA and EPS guidance, and declining margins. Despite strong revenue growth and strategic product development, the reduction in guidance due to tariffs and uncertainties in supply chain adjustments weigh negatively. The Q&A indicates management's evasiveness on key issues, adding to the market's uncertainty. Given the company's small market cap, the stock may react more strongly to these negative factors, leading to a likely decline in stock price over the next two weeks.
Total Revenue $270,000,000 (up $24,000,000 or 9.8% year-over-year) driven by increased contribution from XT Amplify program and growth in SaaS and XPath services.
Product Revenue $145,000,000 (up $12,000,000 or 9% year-over-year) due to strong demand for products, but down $37,000,000 from the previous quarter due to typical seasonality.
Service Revenue $125,000,000 (up $12,000,000 or 10.6% year-over-year) flat compared to the previous quarter.
Non-GAAP Gross Margin 42.1% (down 530 basis points year-over-year) due to lower product revenue volumes and seasonal expenses.
GAAP Earnings Per Share Loss of $0.15 (improved from loss of $0.34 year-over-year) reflecting better revenue performance.
Non-GAAP Earnings Per Share $0.26 (up from $0.03 year-over-year) but down from $0.60 in the previous quarter.
Non-GAAP EBITDA $24,000,000 (up $13,000,000 year-over-year) but down $23,000,000 from the previous quarter due to higher costs and seasonal expenses.
Cash and Cash Equivalents $387,000,000 (up from $369,000,000 as of 12/31/2024) indicating solid cash flow generation.
Free Cash Flow $10,000,000 during the first quarter of 2025.
Accounts Receivable Days 86 days, indicating strong quarterly collections and working capital management.
Inventories $91,000,000 (up $2,000,000 from the prior quarter, down $12,000,000 year-over-year) reflecting inventory management efforts.
Tariff Impact on Non-GAAP EBITDA Expected to be approximately $40,000,000 for 2025, with $5,000,000 anticipated in Q2.
Product Revenue: Product revenues came in at $145,000,000, an increase of $12,000,000 over Q1 2024.
XT Amplify Program: The XT Amplify program continues to gain traction, contributing to revenue growth and customer interest.
New Product Rollout: The XT Amplify product, Xtend, is currently being rolled out and has received favorable responses from customers.
Market Share Expansion: Omnicell is focused on capturing greater market share across inpatient and outpatient settings.
Customer Wins: New customers in Illinois and the Northeast have chosen Omnicell solutions, indicating strong demand.
Government Contracts: The U.S. Department of Veterans Affairs and other federal health facilities are expanding their use of Omnicell solutions.
Recurring Revenue Growth: Omnicell is growing and scaling its predictable recurring revenue.
Supply Chain Optimization: The company is optimizing its supply chain through dual sourcing and near-shoring efforts.
Cash Flow Management: Omnicell generated solid free cash flow of $10,000,000 in Q1 2025.
Tariff Mitigation Strategy: Omnicell is implementing various strategies to mitigate the impact of tariffs, including shifting sourcing to more favorable geographies.
Long-term Growth Strategy: The company remains focused on its long-term growth strategy aligned with the vision of the Autonomous Pharmacy.
Tariff Impact: The company anticipates a tariff impact of approximately $40,000,000 on non-GAAP EBITDA for 2025 due to tariffs on China-based products. This is a significant risk that could affect financial performance.
Supply Chain Challenges: Omnicell sources a meaningful percentage of its subassemblies from China, which exposes the company to tariff risks. The company is working on optimizing its supply chain through dual sourcing and near-shoring efforts.
Regulatory Issues: The company is navigating a fluid tariff environment, which may lead to increased costs and uncertainty in financial projections.
Economic Factors: The current macroeconomic environment poses challenges, including inflation and potential impacts on hospital budgets, which could affect demand for Omnicell's products and services.
Competitive Pressures: Despite the tariff headwinds, Omnicell believes it has a strong competitive position and plans to continue innovating to maintain market share.
Market Share Expansion: Omnicell aims to capture greater market share across inpatient settings, including nursing floors, operating rooms, and procedural areas, while also expanding into outpatient settings such as specialty, retail, and institutional pharmacies.
Recurring Revenue Growth: The company is focused on growing and scaling its predictable recurring revenue.
Omnisphere Development: Omnicell is striving to grow its cloud-based platform, Omnisphere, to connect innovative automation technologies, including the use of AI across the continuum of care.
2025 Non-GAAP EBITDA Guidance: The company anticipates a non-GAAP EBITDA impact of approximately $40 million due to tariffs, leading to a reduction in the upper end of the 2025 non-GAAP EBITDA guidance by $10 million.
2025 Non-GAAP EPS Guidance: The upper end of the non-GAAP earnings per share guidance is reduced by $0.20 due to the expected tariff impact.
Q2 2025 Revenue Guidance: Total revenue is expected to be between $270 million and $280 million, with product revenue between $148 million and $153 million, and service revenue between $122 million and $127 million.
Full Year 2025 Revenue Guidance: Total revenue is expected to be in the range of $1,105 million to $1,155 million, with product bookings anticipated between $500 million and $550 million.
Annual Recurring Revenue Guidance: Year-end 2025 annual recurring revenue is expected to be in the range of $610 million to $630 million.
Shareholder Return Plan: Omnicell is adjusting its guidance for full year 2025 non GAAP EBITDA and non GAAP earnings per share due to anticipated tariff impacts, reducing the upper end of the non GAAP EBITDA guidance by $10,000,000 and the upper end of non GAAP earnings per share guidance by $0.20. The company expects a total tariff impact of approximately $40,000,000 on non GAAP EBITDA for 2025, with $5,000,000 expected in Q2 and the remainder in the second half of the year.
Share Repurchase: The company has repurchased a significant portion of its previously outstanding convertible senior notes, which is expected to result in an approximate $0.20 headwind to non GAAP earnings per share in 2025 compared to 2024.
The earnings call reveals strong financial performance with increased guidance, new product launches, and strategic growth drivers. Despite slight margin declines and cash flow reduction, the company has managed debt well and engaged in stock repurchases. The Q&A highlights positive sentiment towards AI and robotics integration, and a favorable buying environment in hospitals. The reaffirmed guidance and strategic focus on innovative platforms suggest a positive outlook, likely resulting in a 2% to 8% stock price increase given the market cap.
The earnings call highlights strong financial metrics, a positive outlook on product development, and strategic market positioning. Despite concerns about tariffs and Medicaid cuts, the company is mitigating risks through supply chain resiliency and innovative solutions. Guidance remains optimistic, particularly with the potential growth of OmniSphere and IV compounding products. The market cap indicates a more pronounced reaction, suggesting a positive stock movement in the short term.
The earnings call reveals several concerns: a significant tariff impact on financial projections, a reduction in EBITDA and EPS guidance, and declining margins. Despite strong revenue growth and strategic product development, the reduction in guidance due to tariffs and uncertainties in supply chain adjustments weigh negatively. The Q&A indicates management's evasiveness on key issues, adding to the market's uncertainty. Given the company's small market cap, the stock may react more strongly to these negative factors, leading to a likely decline in stock price over the next two weeks.
The earnings call presents a mixed picture: strong revenue growth YoY but a decline QoQ due to seasonality. The guidance is cautious, with flat to modest declines in bookings and revenue. The share repurchase is a positive, but tariff impacts and supply chain concerns weigh on sentiment. The Q&A reveals uncertainty around tariffs and supply chain adjustments, but no slowdown in demand. Given the market cap, the stock is likely to experience a neutral reaction, with the positive and negative factors balancing each other out.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
